SUBSCRIBE
SUBSCRIBE

Reunion Neuroscience

NEWS
NextGen
BioSpace’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Mother covering her face, experiencing depression symptoms
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
The New Jersey-based biopharma will use the funds to support a Phase II study of its serotonergic psychedelic drug candidate in postpartum depression.
May 3, 2024
 · 
2 min read
 · 
Tyler Patchen
IN THE PRESS
Press Releases
Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones
January 6, 2025
 · 
5 min read
Press Releases
Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting
December 12, 2024
 · 
1 min read
Press Releases
Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
October 9, 2024
 · 
4 min read
Press Releases
Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
September 10, 2024
 · 
3 min read
Press Releases
Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
July 23, 2024
 · 
3 min read
Drug Development
Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders
May 20, 2024
 · 
4 min read
Policy
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
March 14, 2023
 · 
3 min read
AWARDS
  • NextGen Class of 2025
JOBS